- Home
- CRML vs PCRX Comparison
CRML vs PCRX Comparison
Compare CRML & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRML
- PCRX
- Stock Information
- Founded
- CRML N/A
- PCRX 2006
- Country
- CRML United States
- PCRX United States
- Employees
- CRML N/A
- PCRX N/A
- Industry
- CRML
- PCRX Biotechnology: Pharmaceutical Preparations
- Sector
- CRML
- PCRX Health Care
- Exchange
- CRML NYSE
- PCRX Nasdaq
- Market Cap
- CRML 298.8M
- PCRX 1.2B
- IPO Year
- CRML N/A
- PCRX 2011
- Fundamental
- Price
- CRML $3.96
- PCRX $22.73
- Analyst Decision
- CRML
- PCRX Buy
- Analyst Count
- CRML 0
- PCRX 8
- Target Price
- CRML N/A
- PCRX $28.38
- AVG Volume (30 Days)
- CRML 8.4M
- PCRX 492.0K
- Earning Date
- CRML 02-01-2025
- PCRX 07-29-2025
- Dividend Yield
- CRML N/A
- PCRX N/A
- EPS Growth
- CRML N/A
- PCRX N/A
- EPS
- CRML N/A
- PCRX N/A
- Revenue
- CRML $476,979.00
- PCRX $702,772,000.00
- Revenue This Year
- CRML N/A
- PCRX $7.92
- Revenue Next Year
- CRML N/A
- PCRX $11.02
- P/E Ratio
- CRML N/A
- PCRX N/A
- Revenue Growth
- CRML 326.80
- PCRX 3.08
- 52 Week Low
- CRML $1.23
- PCRX $11.16
- 52 Week High
- CRML $11.13
- PCRX $27.64
- Technical
- Relative Strength Index (RSI)
- CRML 55.25
- PCRX 36.58
- Support Level
- CRML $2.80
- PCRX $22.23
- Resistance Level
- CRML $3.34
- PCRX $23.91
- Average True Range (ATR)
- CRML 0.46
- PCRX 0.82
- MACD
- CRML -0.05
- PCRX -0.01
- Stochastic Oscillator
- CRML 42.92
- PCRX 22.03
About CRML CRITICAL METALS CORPORATION
Critical Metals Corp is engaged in lithium exploration in Austria. It is focused on the development of its wholly-owned Wolfsberg Lithium Project (the Wolfsberg Project) located in Carinthia, Austria.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.